Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year.
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.